ZA200208406B - A novel P-selectin glycoprotein ligand (PSGL-1) binding protein and uses therefor. - Google Patents

Info

Publication number

ZA200208406B

ZA200208406B ZA200208406A ZA200208406A ZA200208406B ZA 200208406 B ZA200208406 B ZA 200208406B ZA 200208406 A ZA200208406 A ZA 200208406A ZA 200208406 A ZA200208406 A ZA 200208406A ZA 200208406 B ZA200208406 B ZA 200208406B

Authority

ZA

South Africa

Prior art keywords

slic

nucleic acid

polypeptide

protein

acid molecule

Prior art date

2000-03-24

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003446 ligand Substances 0.000 title description 31
• 108010035766 P-Selectin Proteins 0.000 title description 19
• 108091008324 binding proteins Proteins 0.000 title description 2
• 102000008212 P-Selectin Human genes 0.000 title 1
• 102000023732 binding proteins Human genes 0.000 title 1
• 101000687654 Homo sapiens Sorting nexin-20 Proteins 0.000 claims description 753
• 102100024801 Sorting nexin-20 Human genes 0.000 claims description 671
• 150000007523 nucleic acids Chemical class 0.000 claims description 258
• 102000039446 nucleic acids Human genes 0.000 claims description 246
• 108020004707 nucleic acids Proteins 0.000 claims description 246
• 230000000694 effects Effects 0.000 claims description 159
• 238000000034 method Methods 0.000 claims description 142
• 125000003729 nucleotide group Chemical group 0.000 claims description 135
• 239000002773 nucleotide Substances 0.000 claims description 131
• 150000001875 compounds Chemical class 0.000 claims description 106
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 85
• 229920001184 polypeptide Polymers 0.000 claims description 78
• 239000000523 sample Substances 0.000 claims description 74
• 239000013612 plasmid Substances 0.000 claims description 67
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 66
• 239000013598 vector Substances 0.000 claims description 53
• 238000003556 assay Methods 0.000 claims description 52
• 238000012360 testing method Methods 0.000 claims description 52
• 239000012634 fragment Substances 0.000 claims description 50
• 108020004999 messenger RNA Proteins 0.000 claims description 50
• 239000013604 expression vector Substances 0.000 claims description 44
• 230000027455 binding Effects 0.000 claims description 33
• 125000000539 amino acid group Chemical group 0.000 claims description 32
• 150000001413 amino acids Chemical class 0.000 claims description 31
• 238000001514 detection method Methods 0.000 claims description 26
• 230000000295 complement effect Effects 0.000 claims description 25
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
• 239000001963 growth medium Substances 0.000 claims description 5
• 239000002853 nucleic acid probe Substances 0.000 claims description 5
• 238000012258 culturing Methods 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
• 238000000159 protein binding assay Methods 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 description 233
• 210000004027 cell Anatomy 0.000 description 183
• 102000004169 proteins and genes Human genes 0.000 description 153
• 108020004414 DNA Proteins 0.000 description 146
• 235000018102 proteins Nutrition 0.000 description 146
• 230000014509 gene expression Effects 0.000 description 120
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 85
• 239000003795 chemical substances by application Substances 0.000 description 83
• 208000035475 disorder Diseases 0.000 description 65
• 239000003814 drug Substances 0.000 description 51
• 108091028043 Nucleic acid sequence Proteins 0.000 description 48
• 238000009396 hybridization Methods 0.000 description 48
• 241001465754 Metazoa Species 0.000 description 45
• 230000004913 activation Effects 0.000 description 44
• 241000282414 Homo sapiens Species 0.000 description 43
• 230000000692 anti-sense effect Effects 0.000 description 43
• 229940079593 drug Drugs 0.000 description 41
• 230000035772 mutation Effects 0.000 description 41
• 210000001519 tissue Anatomy 0.000 description 35
• 235000001014 amino acid Nutrition 0.000 description 34
• 239000002299 complementary DNA Substances 0.000 description 34
• 108020001507 fusion proteins Proteins 0.000 description 32
• 102000037865 fusion proteins Human genes 0.000 description 31
• 230000001594 aberrant effect Effects 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 29
• 239000012472 biological sample Substances 0.000 description 29
• 239000000203 mixture Substances 0.000 description 29
• 238000003752 polymerase chain reaction Methods 0.000 description 29
• 230000001105 regulatory effect Effects 0.000 description 29
• 238000011282 treatment Methods 0.000 description 29
• 239000013615 primer Substances 0.000 description 26
• 210000000349 chromosome Anatomy 0.000 description 25
• 239000000758 substrate Substances 0.000 description 25
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 24
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 24
• 235000002374 tyrosine Nutrition 0.000 description 24
• 108091034117 Oligonucleotide Proteins 0.000 description 22
• 102000003800 Selectins Human genes 0.000 description 21
• 108090000184 Selectins Proteins 0.000 description 21
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
• 230000004663 cell proliferation Effects 0.000 description 20
• 201000010099 disease Diseases 0.000 description 20
• 102000045777 human SNX20 Human genes 0.000 description 20
• 230000001225 therapeutic effect Effects 0.000 description 20
• 241000699666 Mus <mouse, genus> Species 0.000 description 19
• 230000012010 growth Effects 0.000 description 19
• 230000001404 mediated effect Effects 0.000 description 19
• 238000013508 migration Methods 0.000 description 19
• 108700019146 Transgenes Proteins 0.000 description 18
• 230000003394 haemopoietic effect Effects 0.000 description 18
• 230000003993 interaction Effects 0.000 description 18
• 230000005012 migration Effects 0.000 description 18
• 230000009261 transgenic effect Effects 0.000 description 18
• 230000004927 fusion Effects 0.000 description 17
• 238000003199 nucleic acid amplification method Methods 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• 230000019491 signal transduction Effects 0.000 description 17
• 239000000126 substance Substances 0.000 description 17
• 102000004190 Enzymes Human genes 0.000 description 16
• 108090000790 Enzymes Proteins 0.000 description 16
• 230000003321 amplification Effects 0.000 description 16
• 229940088598 enzyme Drugs 0.000 description 16
• 230000002757 inflammatory effect Effects 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 238000012216 screening Methods 0.000 description 16
• 238000007423 screening assay Methods 0.000 description 16
• -1 theronines Chemical class 0.000 description 16
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 15
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 15
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• 230000004069 differentiation Effects 0.000 description 15
• 239000000463 material Substances 0.000 description 15
• 150000003384 small molecules Chemical class 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 14
• 238000003259 recombinant expression Methods 0.000 description 14
• 108091026890 Coding region Proteins 0.000 description 13
• 102100023472 P-selectin Human genes 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 230000000875 corresponding effect Effects 0.000 description 13
• 238000002744 homologous recombination Methods 0.000 description 13
• 230000006801 homologous recombination Effects 0.000 description 13
• 208000027866 inflammatory disease Diseases 0.000 description 13
• 208000007536 Thrombosis Diseases 0.000 description 12
• 230000004075 alteration Effects 0.000 description 12
• 230000004071 biological effect Effects 0.000 description 12
• 230000001413 cellular effect Effects 0.000 description 12
• 230000001086 cytosolic effect Effects 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 208000018706 hematopoietic system disease Diseases 0.000 description 12
• 230000002974 pharmacogenomic effect Effects 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• 102000053602 DNA Human genes 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 230000001419 dependent effect Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 208000026278 immune system disease Diseases 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 241000588724 Escherichia coli Species 0.000 description 10
• 230000003436 cytoskeletal effect Effects 0.000 description 10
• 210000004408 hybridoma Anatomy 0.000 description 10
• 241000894006 Bacteria Species 0.000 description 9
• 108090000994 Catalytic RNA Proteins 0.000 description 9
• 102000053642 Catalytic RNA Human genes 0.000 description 9
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 239000000427 antigen Substances 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 230000020411 cell activation Effects 0.000 description 9
• 239000012707 chemical precursor Substances 0.000 description 9
• 238000003776 cleavage reaction Methods 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 9
• 210000003917 human chromosome Anatomy 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• 230000000069 prophylactic effect Effects 0.000 description 9
• 108091092562 ribozyme Proteins 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 230000021164 cell adhesion Effects 0.000 description 8
• 210000004292 cytoskeleton Anatomy 0.000 description 8
• 230000029087 digestion Effects 0.000 description 8
• 230000002255 enzymatic effect Effects 0.000 description 8
• 230000002163 immunogen Effects 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 238000013507 mapping Methods 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 244000005700 microbiome Species 0.000 description 8
• 201000000050 myeloid neoplasm Diseases 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 108091008146 restriction endonucleases Proteins 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 238000010561 standard procedure Methods 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 7
• 208000024172 Cardiovascular disease Diseases 0.000 description 7
• 108091033380 Coding strand Proteins 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 239000012636 effector Substances 0.000 description 7
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 238000012544 monitoring process Methods 0.000 description 7
• 102000054765 polymorphisms of proteins Human genes 0.000 description 7
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 230000012292 cell migration Effects 0.000 description 6
• 230000002759 chromosomal effect Effects 0.000 description 6
• 238000001415 gene therapy Methods 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 239000000816 peptidomimetic Substances 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 238000012163 sequencing technique Methods 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 238000013519 translation Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 238000001262 western blot Methods 0.000 description 6
• 102000005720 Glutathione transferase Human genes 0.000 description 5
• 108010070675 Glutathione transferase Proteins 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 108091005461 Nucleic proteins Proteins 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 108010091086 Recombinases Proteins 0.000 description 5
• 102000018120 Recombinases Human genes 0.000 description 5
• 108700008625 Reporter Genes Proteins 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 230000005714 functional activity Effects 0.000 description 5
• 230000004077 genetic alteration Effects 0.000 description 5
• 231100000118 genetic alteration Toxicity 0.000 description 5
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
• 210000004754 hybrid cell Anatomy 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 210000000287 oocyte Anatomy 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 230000004952 protein activity Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 210000001082 somatic cell Anatomy 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 230000009466 transformation Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 238000001086 yeast two-hybrid system Methods 0.000 description 5
• 108020005544 Antisense RNA Proteins 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 108020004635 Complementary DNA Proteins 0.000 description 4
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
• 239000003155 DNA primer Substances 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 108010092694 L-Selectin Proteins 0.000 description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 description 4
• 101710163270 Nuclease Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 150000001720 carbohydrates Chemical group 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 239000003184 complementary RNA Substances 0.000 description 4
• 231100000599 cytotoxic agent Toxicity 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 150000002484 inorganic compounds Chemical class 0.000 description 4
• 229910010272 inorganic material Inorganic materials 0.000 description 4
• 230000005732 intercellular adhesion Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 230000008520 organization Effects 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000002987 primer (paints) Substances 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• 108010092160 Dactinomycin Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 108010024212 E-Selectin Proteins 0.000 description 3
• 102100023471 E-selectin Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 102000004890 Interleukin-8 Human genes 0.000 description 3
• 108090001007 Interleukin-8 Proteins 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• 102000016551 L-selectin Human genes 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 239000000020 Nitrocellulose Substances 0.000 description 3
• 108091092724 Noncoding DNA Proteins 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 108010083644 Ribonucleases Proteins 0.000 description 3
• 102000006382 Ribonucleases Human genes 0.000 description 3
• 102000014400 SH2 domains Human genes 0.000 description 3
• 108050003452 SH2 domains Proteins 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010090804 Streptavidin Proteins 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 239000011543 agarose gel Substances 0.000 description 3
• 230000003466 anti-cipated effect Effects 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 238000000423 cell based assay Methods 0.000 description 3
• 230000033077 cellular process Effects 0.000 description 3
• 238000003200 chromosome mapping Methods 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 239000013068 control sample Substances 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 210000003038 endothelium Anatomy 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 230000001747 exhibiting effect Effects 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000001476 gene delivery Methods 0.000 description 3
• 208000019622 heart disease Diseases 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000007901 in situ hybridization Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000035992 intercellular communication Effects 0.000 description 3
• 229940096397 interleukin-8 Drugs 0.000 description 3
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
• 230000010262 intracellular communication Effects 0.000 description 3
• 230000031146 intracellular signal transduction Effects 0.000 description 3
• 101150066555 lacZ gene Proteins 0.000 description 3
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 3
• 229920001220 nitrocellulos Polymers 0.000 description 3
• 150000002894 organic compounds Chemical class 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000004481 post-translational protein modification Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 125000005630 sialyl group Chemical group 0.000 description 3
• 230000007727 signaling mechanism Effects 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 235000008521 threonine Nutrition 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 229940035893 uracil Drugs 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• 101150084750 1 gene Proteins 0.000 description 2
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 206010003011 Appendicitis Diseases 0.000 description 2
• 208000036490 Arterial inflammations Diseases 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 239000003298 DNA probe Substances 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000025499 G6PD deficiency Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 206010071602 Genetic polymorphism Diseases 0.000 description 2
• 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000031220 Hemophilia Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 206010073734 Microembolism Diseases 0.000 description 2
• HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
• 206010029379 Neutrophilia Diseases 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 239000012807 PCR reagent Substances 0.000 description 2
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• 208000005485 Thrombocytosis Diseases 0.000 description 2
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 208000027276 Von Willebrand disease Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000013060 biological fluid Substances 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 210000000748 cardiovascular system Anatomy 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 238000002742 combinatorial mutagenesis Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 229940000406 drug candidate Drugs 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000004554 glutamine Nutrition 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 210000000224 granular leucocyte Anatomy 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 208000033065 inborn errors of immunity Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000004396 mastitis Diseases 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 230000031864 metaphase Effects 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 230000033607 mismatch repair Effects 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 206010034674 peritonitis Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 238000007747 plating Methods 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 235000013930 proline Nutrition 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 102000016914 ras Proteins Human genes 0.000 description 2
• 108010014186 ras Proteins Proteins 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 235000004400 serine Nutrition 0.000 description 2
• 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
• 230000007781 signaling event Effects 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 239000003656 tris buffered saline Substances 0.000 description 2
• 230000005747 tumor angiogenesis Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
• ZINXKWMTURNPGZ-UHFFFAOYSA-N 3-fluoro-1h-pyrimidine-2,4-dione Chemical compound FN1C(=O)C=CNC1=O ZINXKWMTURNPGZ-UHFFFAOYSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
• 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101150010738 CYP2D6 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000001327 Chemokine CCL5 Human genes 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 241000252203 Clupea harengus Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 108010051219 Cre recombinase Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020001738 DNA Glycosylase Proteins 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 102000028381 DNA glycosylase Human genes 0.000 description 1
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102100021238 Dynamin-2 Human genes 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108010046276 FLP recombinase Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
• 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 108010042653 IgA receptor Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000037447 Leukocyte adhesion deficiency type III Diseases 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 208000032234 No therapeutic response Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108010054395 P-selectin ligand protein Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 101150006914 TRP1 gene Proteins 0.000 description 1
• 241000223892 Tetrahymena Species 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007984 Tris EDTA buffer Substances 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
• 240000006677 Vicia faba Species 0.000 description 1
• 235000010749 Vicia faba Nutrition 0.000 description 1
• 235000002098 Vicia faba var. major Nutrition 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• DLYSYXOOYVHCJN-UDWGBEOPSA-N [(2r,3s,5r)-2-[[[(4-methoxyphenyl)-diphenylmethyl]amino]methyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphonamidous acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NC[C@@H]1[C@@H](OP(N)O)C[C@H](N2C(NC(=O)C(C)=C2)=O)O1 DLYSYXOOYVHCJN-UDWGBEOPSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000000078 anti-malarial effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940033495 antimalarials Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000009118 appropriate response Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000010420 art technique Methods 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000008711 chromosomal rearrangement Effects 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000000749 co-immunoprecipitation Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 102000033815 complement binding proteins Human genes 0.000 description 1
• 108091009760 complement binding proteins Proteins 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 150000002254 galactosylceramides Chemical class 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000011223 gene expression profiling Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000010005 growth-factor like effect Effects 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 235000019514 herring Nutrition 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000000503 lectinlike effect Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 description 1
• 201000008103 leukocyte adhesion deficiency 3 Diseases 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000008185 minitablet Substances 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 101150029137 mutY gene Proteins 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000011330 nucleic acid test Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 125000002524 organometallic group Chemical group 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 230000009120 phenotypic response Effects 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 150000003148 prolines Chemical class 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 229940076376 protein agonist Drugs 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 235000021251 pulses Nutrition 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011536 re-plating Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 231100000004 severe toxicity Toxicity 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 238000012409 standard PCR amplification Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
• 238000003161 three-hybrid assay Methods 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 230000006107 tyrosine sulfation Effects 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 210000004269 weibel-palade body Anatomy 0.000 description 1
• WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1